Patient, Sample

DOB: 7/22/1984
Order Number: 219
Report Date: 10/10/2019
Clinician: Sample Clinician
Reference: 1456CIP

Questions? Call 855.891.9415 or email medinfo@assurexhealth.com

TEST INFORMATION

The buccal swab sample was collected on 10/8/2019 and received in the laboratory on 10/9/2019. Genomic DNA was isolat[illegible]d the relevant g[illegible]mic regions were amplified by polymerase chain reaction (PCR). Analysis of CYP2D6 deletion and duplication, HLA-B*1502 and SLC6A[illegible]s completed by [illegible]trophoresis of PCR products. Analysis of CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, HTR2A, rs1061235 (indicating pre[illegible] of the HLA-A*[illegible] allele or certain HLA-A*33 alleles), UGT1A4 and UGT2B15 was completed by using iPLEX MassARRAY® technology (Agena Bioscience[illegible] followi[illegible]netic variants ma[illegible] be detected in the assay: CYP1A2 -3860G>A (NG_008431.1:g.28338G>A), -2467T>delT (NM_000761.4:c.-1635delT), -739T[illegible]M[illegible]761.4:c.-10+103T[illegible] -729C>T (NM_000761.4:c.-10+113C>T), -163C>A (NM_000761.4:c.-9-154C>A), 125C>G (NM_000761.4:c.125C>G), 558[illegible]M_000761.4:c.55[illegible]), 2116G>A (NM_000761.4:c.1042G>A), 2473G>A (NM_000761.4:c.1130G>A), 2499A>T (NM_000761.4:c.1156A>T), 3497G>A [illegible]000761.4:c.1[illegible]>A), 3533G>A (NM_000761.4:c.1253+1G>A), 5090C>T (NM_000761.4:c.1291C>T), 5166G>A (NM_000761.4:c.1367G>A), 5347C>T ([illegible]00761.4:[illegible]8C>T); CYP2B6 *1, *4 (NM_000767.4:c.785A>G), *6 (NM_000767.4:c.516G>T; c.785A>G), *9 (NM_00076[illegible]:c.516G>T); CYP2C19 *1, *2 (N[illegible]76[illegible].681G>A), *3 (NM_000769.2:c.636G>A), *4 (NM_000769.2:c.1A>G), *5 (NM_000769.2:c.1297C>T),*6 (NM[illegible]769.2:c.395G>A), *7 (NM_00076[illegible]9+2T>A), *8 (NM_000769.2:c.358T>C), *17 (NM_000769.2:c.-806C>T); CYP2C9 *1, *2 (NM_000771.3:c.430C>T), *3 ([illegible]00771.3:c.1075A>C), *4 (NM_000[illegible]1.3:c.1076T>C), *5 (NM_000771.3:c.1080C>G), *6 (NM_000771.3:c.817delA); CYP2D6 *1, *2 (NM_000106.5:c.886C>T; c.[illegible]G>C), *2A (NM_000106.5:c.-1584C>G; c.886C>T; c.1457G>C), *3 (NM_000106.5:c.775delA), *4 (NM_000106.5:c.506-1G>A; c.100C>T; c.1457G>C), *5 ([illegible]2D6 Deletion), *6 ([illegible]000106.5:c.454delT), *7 (NM_000106.5:c.971A>C), *8 (NM_000106.5:c.505G>T; c.886C>T; c.1457G>C) [illegible]00106.5:c.[illegible]3delAAG), *1[illegible]NM_000106.5:c.100C>T; c.1457G>C), *11, *12 (NM_000106.5:c.124G>A; c.886C>T; c.1457G>C), *14 (NM_000[illegible].c.505G[illegible].886C>T; c[illegible]G>C), *1[illegible] (NM_000106.5:c.320C>T; c.886C>T; c.1457G>C), *41 (NM_000106.5:c.985+39G>A; c.886C>T; c.1457G[illegible] gene duplic[illegible]; CYP3A4 [illegible]13 [illegible]_017460.5:c.1247C>T), *15A (NM_017460.5:c.485G>A), *22 (NM_017460.5:c.522-191C>T); HLA-B*1502; rs1[illegible]35 (NM_002116[illegible]66A>T); HTR2[illegible]G>A (NM_000621.4:c.-998G>A); SLC6A4 L, S; UGT1A4 *1, *3 (NM_007120.2:c.142T>G); UGT2B15 *1, *2 (NM[illegible]076.3:c.253G>T). T[illegible]ollowing rare gene[illegible] variants have not been observed by the Assurex Health, Inc. laboratory: CYP1A2 125C>G, 558C>A; CYP2C19 *7.

This test was developed and its performance characteristics deter[illegible]ed by Assur[illegible]alth[illegible]as not been cleared or approved by the U.S. Food and Drug Administration.

These interpretations are based upon data available in scientific litera[illegible] a[illegible]escribing info[illegible]on for the relevant drugs. Interpretations are, in some instances, based on data regarding the pharmacokinetic, pharmacodynamic an[illegible]harm[illegible]genomics pr[illegible]s of a drug derived from non-clinical studies (e.g. *in vitro* studies). Findings from studies performed in a non-clinical setting or clin[illegible] stud[illegible]olving healt[illegible]jects are not necessarily indicative of clinical performance in a particular patient.

This report was reviewed and verified on 10/10/[illegible]

Nina King

Nina E. King, PhD, HCLD(ABB[illegible]RCC), CQ(NYSDOH)

Disclaimer of Liability
The information contained in this [illegible]rt is provided [illegible]ice and does not constitute medical advice. At the time of report generation this information is believed to be current and is based upon pu[illegible]ed resea[illegible]owe[illegible]rch data evolves and amendments to the prescribing information of the drugs listed will change over time. While this report is believ[illegible]o be a[illegible]ate and complete as of the date issued, THE DATA IS PROVIDED "AS IS", WITHOUT WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCL[illegible]NG [illegible]THOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE[illegible]l advice must be[illegible]d to the specific circumstances of each case, the treating healthcare provider has ultimate responsibility for all treatment decisio[illegible]ade with regard to a patient[illegible]uding any made on the basis of a patient's genotype.

Ge[illegible]ght Psychotropic is [illegible]red by U.S[illegible]tent No. 9,111,028

Ge[illegible] testing w[illegible]pleted by [illegible]LIA an[illegible] CAP accredited laboratory in the United States located at:
600[illegible]omery Road
Mason, [illegible]040

Customer Service
Please contact 855.891.94[illegible]medinfo@assurexhealth.com for assistance with report interpretation. For all other inquires please contact 866.757.9204 or support@assure[illegible].

GeneSight Psychotropic Test Version: 3.0.2